| Treatment . | CD ratio . | DA ratio . | Dmicro (µm2/s) × 0.001 . | fmicro . | R (μm) . | ncella . | Nexpb . |
|---|---|---|---|---|---|---|---|
| Ctr | 1.0 ± 0.1 | 1.0 ± 0.1 | 10.9 ± 0.6 | 0.21 ± 0.02 | 0.322 ± 0.005 | 224 | 10 |
| VIP | 0.50 ± 0.05c | 2.7 ± 0.4d | 3.3 ± 0.2c | 0.40 ± 0.03d | 0.279 ± 0.005c | 164 | 8 |
| CCh | 0.38 ± 0.08c | 2.5 ± 0.3d | 4.77 ± 0.6c | 0.35 ± 0.04d | 0.283 ± 0.004c | 40 | 2 |
| COase +VIP | 0.87 ± 0.08 | 1.0 ± 0.1 | 10.7 ± 0.7 | 0.18 ± 0.02 | 0.303 ± 0.005 | 112 | 4 |
| Ami +VIP | 1.4 ± 0.2d | 0.50 ± 0.07c | 18.0 ± 1.0d | 0.14 ± 0.01c | 0.335 ± 0.005 | 85 | 4 |
| Treatment . | CD ratio . | DA ratio . | Dmicro (µm2/s) × 0.001 . | fmicro . | R (μm) . | ncella . | Nexpb . |
|---|---|---|---|---|---|---|---|
| Ctr | 1.0 ± 0.1 | 1.0 ± 0.1 | 10.9 ± 0.6 | 0.21 ± 0.02 | 0.322 ± 0.005 | 224 | 10 |
| VIP | 0.50 ± 0.05c | 2.7 ± 0.4d | 3.3 ± 0.2c | 0.40 ± 0.03d | 0.279 ± 0.005c | 164 | 8 |
| CCh | 0.38 ± 0.08c | 2.5 ± 0.3d | 4.77 ± 0.6c | 0.35 ± 0.04d | 0.283 ± 0.004c | 40 | 2 |
| COase +VIP | 0.87 ± 0.08 | 1.0 ± 0.1 | 10.7 ± 0.7 | 0.18 ± 0.02 | 0.303 ± 0.005 | 112 | 4 |
| Ami +VIP | 1.4 ± 0.2d | 0.50 ± 0.07c | 18.0 ± 1.0d | 0.14 ± 0.01c | 0.335 ± 0.005 | 85 | 4 |